EVOK

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.39
Percentage change 9.03	%

Peers: MNOV GERN EYPT CASI LPCN CARA DRRX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.09	Insider Own	4.59%	Shs Outstand	1.49M	Perf Week	13.77%
Market Cap	7.63M	Forward P/E	9.81	EPS next Y	0.48	Insider Trans	0.00%	Shs Float	1.42M	Perf Month	10.56%
Income	-6.15M	PEG	-	EPS next Q	-0.63	Inst Own	15.46%	Short Float	1.77%	Perf Quarter	11.58%
Sales	8.62M	P/S	0.89	EPS this Y	85.77%	Inst Trans	-26.35%	Short Ratio	0.06	Perf Half Y	-16.83%
Book/sh	4.90	P/B	0.96	EPS next Y	112.06%	ROA	-55.86%	Short Interest	0.03M	Perf Year	-68.85%
Cash/sh	7.00	P/C	0.67	EPS next 5Y	40.00%	ROE	-349.91%	52W Range	3.54 - 15.13	Perf YTD	-62.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.68%	ROI	-140.11%	52W High	-68.87%	Beta	0.16
Dividend TTM	-	Quick Ratio	1.39	Sales past 5Y	1418.11%	Gross Margin	96.55%	52W Low	33.05%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	1.44	EPS Y/Y TTM	59.40%	Oper. Margin	-68.45%	RSI (14)	53.34	Volatility	8.07% 6.46%
Employees	4	Debt/Eq	1.14	Sales Y/Y TTM	100.35%	Profit Margin	-71.33%	Recom	1.00	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	84.58%	Payout	-	Rel Volume	0.10	Prev Close	4.32
Sales Surprise	-20.96%	EPS Surprise	-147.37%	Sales Q/Q	69.83%	Earnings	Nov 07 AMC	Avg Volume	387.02K	Price	4.71
SMA20	7.91%	SMA50	-6.15%	SMA200	-17.03%	Trades		Volume	38,085	Change	9.03%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-20	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Mar-05-19	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-08-18	Reiterated	B. Riley FBR, Inc.	Buy	$10 → $5
Oct-19-17	Resumed	FBR & Co.	Buy	$10
Mar-16-17	Reiterated	Rodman & Renshaw	Buy	$6 → $9
Jan-30-17	Upgrade	Laidlaw	Neutral → Buy	$8
Jan-05-17	Upgrade	Rodman & Renshaw	Neutral → Buy	$2.50 → $6
Dec-23-16	Reiterated	Rodman & Renshaw	Neutral	$2 → $2.50
Jul-19-16	Reiterated	FBR Capital	Outperform	$17 → $9
Jul-19-16	Downgrade	Noble Financial	Buy → Hold
Jul-18-16	Downgrade	Rodman & Renshaw	Buy → Neutral	$2
Mar-16-16	Initiated	Northland Capital	Outperform
Mar-14-16	Reiterated	Ascendiant Capital Markets	Buy	$11 → $12
Feb-17-16	Resumed	FBR Capital	Outperform	$17
Dec-03-14	Reiterated	MLV & Co	Buy	$12.50 → $14
Nov-07-14	Initiated	MLV & Co	Buy	$12.50
Apr-22-14	Initiated	Laidlaw	Buy	$19
Nov-19-13	Initiated	Aegis Capital	Buy	$60

Show Previous Ratings

Dec-03-24 08:30AM	Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI (GlobeNewswire)
Nov-07-24 04:05PM	Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-28-24 01:39PM	Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis (GuruFocus.com) +33.58%
07:00AM	Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI (GlobeNewswire)
Oct-23-24 08:30AM	Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting (GlobeNewswire) -5.00%
08:30AM	Loading…
Oct-22-24 08:30AM	Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors (GlobeNewswire)
Oct-01-24 08:30AM	Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion (GlobeNewswire)
Sep-21-24 02:38AM	Nantahala Capital Management's Recent Transaction in Evoke Pharma Inc (GuruFocus.com)
Sep-19-24 02:20PM	Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments (GlobeNewswire)
Sep-09-24 08:30AM	Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference (GlobeNewswire) +6.20%
Sep-04-24 09:20AM	Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 08:00AM	Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-08-24 08:30AM	Evoke Pharma, Inc. Supports Gastroparesis Awareness Month (GlobeNewswire) +7.21%
Jul-30-24 08:30AM	Evoke Pharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -16.40%
Jun-17-24 08:30AM	Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI (GlobeNewswire) +11.93%
04:02PM	Loading…
May-16-24 04:02PM	Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
May-14-24 10:53PM	EVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:15PM	Evoke Pharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-17-24 08:30AM	Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications (GlobeNewswire) +16.81%
Mar-21-24 04:15PM	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer (GlobeNewswire)
Mar-15-24 01:58PM	Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.09%
06:56AM	Q4 2023 Evoke Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +5.24%
Mar-07-24 04:10PM	Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 (GlobeNewswire)
Feb-14-24 07:30AM	Evoke Pharma Announces Closing of $7.5 Million Public Offering (GlobeNewswire)
Feb-09-24 07:30AM	Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million (GlobeNewswire) +15.95%
Nov-30-23 12:16PM	Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray (News Direct)
Nov-27-23 08:30AM	Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent (GlobeNewswire)
Nov-14-23 08:30AM	United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI (GlobeNewswire) +7.20%
Nov-09-23 08:30AM	Evoke Pharma Reports Third Quarter 2023 Financial Results (GlobeNewswire) +10.34%
08:30AM	Loading…
Oct-31-23 08:30AM	Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023 (GlobeNewswire)
Oct-23-23 06:30AM	7 Under-the-Radar Growth Stocks Ready to Make a Splash (InvestorPlace) -8.05%
Oct-18-23 08:30AM	Evoke Pharma's Abstract Entitled Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting (GlobeNewswire)
Sep-14-23 08:30AM	Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI® (GlobeNewswire)
Aug-10-23 08:30AM	Evoke Pharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 08:30AM	Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting (GlobeNewswire) -7.84%
Jul-25-23 08:30AM	Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting (GlobeNewswire)
Jun-14-23 08:30AM	Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment (GlobeNewswire) -9.44%
May-15-23 04:05PM	Evoke Pharma Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:00AM	Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources (GlobeNewswire)
May-04-23 08:30AM	Evoke Pharmas Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023 (GlobeNewswire)
May-01-23 08:30AM	New GIMOTI Patent Listed in FDA Orange Book (GlobeNewswire)
Apr-20-23 08:30AM	United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI (GlobeNewswire)
Apr-06-23 08:30AM	Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent (GlobeNewswire)
Mar-24-23 07:36AM	Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2022 Earnings Call Transcript (Insider Monkey) -11.83%
Mar-23-23 08:30AM	Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023 (GlobeNewswire)
Mar-21-23 04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.53% -15.16%
Mar-15-23 08:30AM	Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023 (GlobeNewswire) -5.98%
Feb-21-23 07:00AM	Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session (GlobeNewswire)
Jan-30-23 07:00AM	Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti (GlobeNewswire)
Jan-18-23 08:30AM	Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023 (GlobeNewswire) +12.62%
Dec-07-22 08:30AM	USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis (GlobeNewswire) +36.70%
Nov-30-22 08:30AM	Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® (GlobeNewswire)
Nov-12-22 08:03AM	Evoke Pharma Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 04:30PM	Edited Transcript of EVOK.OQ earnings conference call or presentation 9-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents) +13.04%
04:05PM	Evoke Pharma Reports Record Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:30AM	Evoke Pharma to Report Third Quarter Results on November 9, 2022 (GlobeNewswire)
Oct-20-22 08:44AM	Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting (GlobeNewswire)
Sep-20-22 08:30AM	Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI (GlobeNewswire)
Sep-14-22 08:30AM	GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award (GlobeNewswire)
Sep-06-22 08:30AM	Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 08:30AM	Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution (GlobeNewswire)
Aug-10-22 04:30PM	Edited Transcript of EVOK.OQ earnings conference call or presentation 10-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents) -9.00%
04:05PM	Evoke Pharma Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 08:30AM	Evoke Pharma to Report Second Quarter Results on August 10, 2022 (GlobeNewswire)
Aug-01-22 08:30AM	Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD) (GlobeNewswire) +6.89%
Jul-06-22 08:30AM	Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use (GlobeNewswire) +6.51%
Jun-15-22 08:30AM	Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program (GlobeNewswire) +47.06%
Jun-08-22 08:30AM	Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update (GlobeNewswire)
May-23-22 07:00AM	Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported (GlobeNewswire) -11.53%
May-18-22 08:30AM	Patient Experience Survey Reported Positive Findings for GIMOTI® (GlobeNewswire) -7.99%
May-17-22 08:30AM	Evoke Pharma to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +5.42%
May-10-22 04:05PM	Evoke Pharma Reports First Quarter 2022 Financial Results (GlobeNewswire) -7.90% -21.74%
May-03-22 08:30AM	Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022 (GlobeNewswire) -6.21%
Apr-26-22 11:36AM	Warner Bros. Discovery adds 2 million subscribers in first earnings report (Yahoo Finance Video) +118.50%
08:54AM	Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray (Benzinga)
08:30AM	Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® (GlobeNewswire)
Apr-19-22 08:30AM	Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List (GlobeNewswire) +14.73%
Mar-10-22 08:30AM	Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape (GlobeNewswire)
Mar-08-22 04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -12.82%
Mar-01-22 08:30AM	Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 (GlobeNewswire) -7.14%
Feb-24-22 08:30AM	Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022 (GlobeNewswire)
Feb-17-22 08:30AM	GIMOTI® Commercialization Update (GlobeNewswire)
Feb-02-22 08:30AM	Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI (GlobeNewswire)
Jan-04-22 08:30AM	Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire) -5.57%
Nov-10-21 04:05PM	Evoke Pharma Reports Third Quarter 2021 Financial Results (GlobeNewswire) -6.92% -13.64%
Nov-03-21 08:30AM	Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
Oct-20-21 08:30AM	Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study (GlobeNewswire)
Sep-29-21 08:30AM	Evoke Pharmas Commercial Partner EVERSANA, Receives PM360s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI (GlobeNewswire) -6.11%
Sep-10-21 07:53AM	Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) +5.61%
Sep-01-21 08:30AM	Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-16-21 07:20AM	24 Stocks Moving in Monday's Pre-Market Session (Benzinga)
Aug-12-21 04:05PM	Evoke Pharma Reports Second Quarter 2021 Financial Results (GlobeNewswire) +19.64%
Aug-05-21 08:30AM	Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021 (GlobeNewswire)
Aug-02-21 08:30AM	Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders (IFFGD) August Gastroparesis Awareness Month (GlobeNewswire)
Jul-14-21 08:30AM	Evoke Pharma Launches Gimoti® Patient and Physician Experience Program (GlobeNewswire)
Jun-29-21 08:30AM	Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGDs Industry Council (GlobeNewswire) -8.22%
Jun-15-21 08:30AM	Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study (GlobeNewswire)
Jun-08-21 08:30AM	Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti® (GlobeNewswire) +5.34%
Jun-02-21 08:30AM	Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti® (GlobeNewswire) -5.15%

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Evoke Pharma Inc

Upgrade your FINVIZ experience